Efficacy and tolerability of α-galactosidase in treating gas-related symptoms in children: a randomized, double-blind, placebo controlled trial by unknown
Di Nardo et al. BMC Gastroenterology 2013, 13:142
http://www.biomedcentral.com/1471-230X/13/142RESEARCH ARTICLE Open AccessEfficacy and tolerability of α-galactosidase in
treating gas-related symptoms in children: a
randomized, double-blind, placebo controlled trial
Giovanni Di Nardo1†, Salvatore Oliva1†, Federica Ferrari1, Saverio Mallardo1, Giovanni Barbara2, Cesare Cremon2,
Marina Aloi1 and Salvatore Cucchiara1*Abstract
Background: Gas-related symptoms represent very common complaints in children. The reduction of gas
production can be considered as a valuable target in controlling symptoms. α-galactosidase has been shown to
reduce gas production and related symptoms in adults. To evaluate the efficacy and tolerability of α-galactosidase
in the treatment of gas-related symptoms in pediatric patients.
Methods: Single center, randomized, double-blind, placebo-controlled, parallel group study performed in tertiary
care setting. Fifty-two pediatric patients (32 female, age range 4–17) with chronic or recurrent gas-related symptoms
were randomized to receive placebo (n = 25) or α-galactosidase (n = 27). Both treatments were given as drops or
tablets, according to body weight for 2 weeks. The primary endpoint was the reduction in global distress measured by
the Faces Pain Scale-Revised (FPS-R) at the end of treatment compared to baseline. Secondary endpoints were the
reduction in severity and frequency of gas-related symptoms as recorded by parents and/or children.
Results: α-galactosidase significantly reduced global distress (p = 0.02) compared to placebo. The digestive enzyme
decreased the number of days with moderate to severe bloating (p = 0.03) and the proportion of patients with
flatulence (p = 0.02). No significant differences were found for abdominal spasms and abdominal distension. No adverse
events were reported during treatment.
Conclusions: Although larger and longer trials are needed to confirm this result, α-galactosidase seems to be a safe,
well tolerated and effective treatment for gas-related symptoms in the pediatric population.
Trial registration: ClinicalTrials.gov, NCT01595932
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Most patients with functional gastrointestinal disorders,
including those with irritable bowel syndrome, complain
of gas-related symptoms, e.g. bloating, abdominal disten-
tion, and flatulence [1]. Indeed, more than 20% of the gen-
eral population suffers from abdominal pain or discomfort
and 16% from bloating or distension [2] with no evidence
of any inflammatory, anatomic, metabolic or neoplastic
process that explains the subject’s symptoms. Intestinal* Correspondence: salvatore.cucchiara@uniroma1.it
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reproduction in any medium, provided the orgas-related symptoms are generally not considered to be a
severe medical problem but can negatively affect quality
of life, even in pediatric age [3].
The mechanism underlying gas-related disorders is not
well understood. As a result, the best treatment is still not
well defined [4,5]. Bloating is the sensation of trapped gas
and tightness in the abdomen which is exacerbated by
meals and fluctuates in intensity during the day. It may be
associated with distension (an objective increase in waist
size) and flatulence. Flatulence or gas build up in the
intestine is typically caused by the fermentation of
undigested food and may cause voluntary or involuntary
passing of gas [6].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Study flow chart.
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intestine may represent an effective therapeutic strategy
for the management of gas-related symptoms when their
cause depends, at least in part, on gas hyper-production.
There are different strategies that may reduce intestinal
gas. Current approaches are based on dietary changes and
life-style factors; administration of simethicone; activated
charcoal and probiotics [7-12]. However in most cases
results are unsatisfactory.
The food enzyme, α-galactosidase, derived from Asper
gillus niger mold, acts in the gastrointestinal tract by
breaking down specific non-absorbable oligosaccharides
before they are metabolized by colonic bacteria [13]. As
a result, this agent may be useful to reduce the amount
of fermentable substrates in the colon and prevent the
overproduction of gas associated with meals. Obviously
the same effect could be obtained by selecting foods
which do not contain those specific non-absorbable
oligosaccharides. However this selection is not easy and
may lead to the elimination of healthy food (cereals,
legumes and vegetables).
There are some data supporting the efficacy of
α-galactosidase in reducing breath hydrogen (a measure of
intestinal gas production) and in preventing gas formation
in the colon and related disturbances [14,15]. However, the
studies are available only in adult populations.
The aim of this study was to evaluate the efficacy and
tolerability of α-galactosidase in pediatric patients with
predominant gas-related symptoms.
Methods
This was a single center, randomized, double blind,
placebo-controlled, parallel group study performed in ter-
tiary care setting. Fifty two pediatric out patients (32
female) with gas-related disturbances at least once per
week over the last 12 weeks, were included in the study.
Exclusion criteria were: 1) any suspected episodes of
hypersensitivity/allergy; 2) any chronic organic disorders, as
assessed by full clinical history and examination, and
supported by normal results of initial limited laboratory
investigation including complete blood cell count, erythro-
cyte sedimentation rate, C-reactive protein, blood glucose,
amylase and lipase, tissue transglutaminase antibodies with
total serum IgA; 3) inability of the parent to comprehend
the full nature and purpose of the study and unwillingness
to co-operate with the Investigator; 4) patients who have
used any drug affecting GI motility or intestinal microbiota
during the previous 4 weeks.
According to previous pediatric studies about functional
gastrointestinal disorders that included subjects with at
least 8 years of age, we divided the study population
into <8 and >8 years [16,17].
Each potentially eligible patient was invited to discuss
the study in detail. Figure 1 shows the patient flow.After informed consent, eligible patients entered a
baseline period of 1 week during which they recorded data
on a daily basis in a questionnaire/diary provided at study
entry by the physician. At the end of the baseline period,
patients returned to the centre where they were random-
ized in a double-blinded fashion to receive placebo (n = 25)
or α-galactosidase (n = 27) (Sinaire, Promefarm) according
to a computer-generated random allocation. The dose was
provided by the manufacturer in the investigator brochure
and is proportional to the adult dose based on body weight
class. Both treatments were given as drops or tablets
according to body weight: 4 or 8 drops were administered
to children with body weight lower than 20 kg and to
children with body weight between 20 and 40 kg, respect-
ively. One tablet was administered to children with body
weight over 40 kg. The treatment was administered at the
beginning of each meal 3 times a day for 2 weeks. No medi-
cations were allowed for the duration of the study. As part
of the initial evaluation, a careful dietary history, including
assessment of fibre intake, was conducted. No changes in
any of the dietary habits of the patients were allowed
throughout the duration of the study. Children underwent
follow-up 2 weeks after the end of treatment. We have
evaluated the global distress associated with gas-related
symptoms (bloating, flatulence, abdominal distension and
abdominal spasms) by means of validated visual score,
i.e., Faces Pain Scale-Revised (FPS-R). The FPS-R has been
shown to be reliable for assessment of the intensity of
children’s pain age 4 or 5 onward [18]. A parent-report
assessment was performed for children 4 years of age and
older (but less than 10 years), while a self-report assessment
was performed for children and adolescents 10 years of age
and older. Parents and/or patients recorded symptoms 3
times daily (7–8 am, 2–3 pm, 6–7 pm) during the treat-
ment. It is well established that relatively few symptoms
may be recorded by diaries and ratings can be performed
only at a fixed time [19]. Bloating, flatulence (wind), visible
distension and spasms were rated (0 = absent; 5 = very
severe) according to intensity and frequency of episodes by
parent and/or child using a daily diary chart. Scores of 4 or
more were associated to severe bloating. Symptomatic




(N = 27) (N = 25)
Demographic data
Gender: n (%)
male 11 (41%) 9 (36%)
0.73
female 16 (59%) 16 (64%)
Age (yrs): n (%)
<8 12 (44%) 10 (40%)
0.75
> = 8 15 (56%) 15 (60%)
Weight (kg): n (%)
≤20 9 (33%) 7 (28%)
0.92>20, ≤40 7 (26%) 7 (28%)
>40 11 (41%) 11 (44%)
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flatulence.
A “physician’s overall evaluation” was made by simple
questions addressed to the child/parent “How did you feel
during the treatment as compare to the period before?” at
the end of treatment and “How did you feel as compared to
the treatment period?” at the end of follow-up and asked to
select a category response as follows: completed or marked
improvement, mild improvement, unchanged or worse.
The primary outcome measure was reduction in the
FPS-R at the end of treatment compared to baseline. The
reduction in proportion of patients with relevant symptoms
is the secondary outcome measure.
The study protocol was defined in accordance with the
Declaration of Helsinki and approved by the ethical
committee of the University Hospital Umberto I in Rome.
Written informed consent was obtained from parents of all
children; children over 12 years of age signed a statement
of assent.
Statistical analysis
By estimating for the primary endpoint a standard deviation
of 1.25 and a targeted difference in the mean scores
between groups of 1, a type-I error of 5%, a power of 80%
and a drop-out rate of 5%, the number of patients to be
enrolled in each group was 26.
All characteristics were summarized by usual descriptive
statistics such as mean and standard deviation for
continuous variables and rates for categorical variables.
Two-sided t-test was used to compare the means of
continuous variables; chi square test was used to compare
the rates of categorical measures.
Values of p-value smaller than 0.05 were considered
statistically significant.
Results
Fifty-two patients completed the trial (32 females, median
age 8 yrs, range 4–17 yrs). The demographic and baseline
data did not differ between the two study groups (Tables 1
and 2). The mean FPS-R decreased more in the
α-galactosidase than placebo group; the difference between
the FPS-R score change in the two groups was statistically
significant (p = 0.02) (Table 2). The FPS-R score improved
more in the α-galactosidase than placebo group, even if the
difference was not statistically significant (Table 3). Only in
3 (11%) patients treated with α-galactosidase, FPS-R score
worsened by more than 0.5 units (Figure 2).
The number of days with moderately to severe bloating
was significantly lower in the α-galactosidase than placebo
group (p = 0.03) (Table 2).
The trend for worse score along the day was common for
both groups. We did not find significant differences
between the active and placebo at any single time
point: bloating scores were better in the morning (α-galactosidase 1.8 ± 1.5, placebo 2.1 ± 1.2), worse in the
afternoon (α-galactosidase 2.1 ± 1.7, placebo 2.1 ± 1.1) and
in the evening (α-galactosidase 2.1 ± 1.9 placebo 2.3 ± 1.1).
The scores were lower with α-galactosidase even if no
difference was statistically significant.
α-galactosidase reduced the proportion of patients with
significant flatulence compared to placebo during treat-
ment (p = 0.02) but no difference was seen for abdominal
distension and spasms (Table 2). Similarly, no change was
observed in the daily bowel movements after treatment
with α-galactosidase (0.9 ± 0.4) and placebo (1.0 ± 0.3) as
compared to baseline (α-galactosidase 1.0 ± 0.4; placebo
1.1 ± 0.5).
According to physician’s overall evaluation, children
receiving α-galactosidase had higher rates of improvement
(67%) than placebo (52%) but the difference was not
statistically significant. At the end of follow-up, about half
the patients in both groups did not change and about 40%
of patients in both groups worsened with no significant
difference in both groups (Figure 3).
Both treatments were well tolerated. No adverse effects
were reported during the study.
Discussion
This randomized placebo-controlled study provides evi-
dence that oral α-galactosidase can improve gas-related
symptoms in children and adolescents. The efficacy of
α-galactosidase was supported by a significant and parallel
decrease in the severity of bloating and FPS-R score. We
used the FPS-R scale in order to measure the overall
degree of discomfort associated with gas-related symp-
toms in everyday life. This could be considered acceptable
as, in our patients, bloating was the main symptom whilst
abdominal pain/spasm and altered bowel habit were only
occasionally present.
The significant decrease of FPS-R score occurring in
the active group and the marginal change in the placebo
Table 2 Rates of symptoms and Global Distress assessed by FPS-R at baseline and after treatment
Symptoms





(N = 27) (N = 25) (N = 27) (N = 25)
Flatulence*: n, (%) 16 (59%) 12 (48%) p = 0.42 5 (19%) 12 (48%) p = 0.02^
Abdominal distension**: n, (%) 12 (44%) 14 (56%) p = 0.41 8 (30%) 11 (44%) p = 0.36
Abdominal spasm***: n, (%) 14 (52%) 14 (56%) p = 0.76 4 (15%) 4 (16%) p = 0.91
FPS-R†, mean ± SD 2.8 ± 1.8 2.3 ± 0.9 p = 0.22 2.0 ± 1.7 2.1 ± 1.1 p = 0.73
Difference between FPS-R at baseline and after treatment −0.8 ± 1.1 −0.2 ± 0.8 p = 0.02^
Number of days with severe bloating during treatment (mean ± SD) 3.4 ± 3.6 5.4 ± 3.4 p = 0.03^
*patients with significant episodes (score of > 2) of flatulence ≥ 3 days/week.
**patients with visible abnormal distension ≥ 3 days/week.
***patients with abdominal spasm ≥ 3 days/week.
†mean of 21 measurements for each patient.
^p value < 0.05 was considered statistically significant.
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dase. The similar score values at end of treatment should
be evaluated taking into account the apparent imbalance
in the baseline FPS-R.
The significant effect on bloating was also confirmed by
a reduction in the number of days with severe episodes of
bloating. In the opinion of the authors, 2 less days of
bloating over the week in the alpha-galactosidase group as
compared to placebo would be clinically significant.
Gas-related symptoms are common medical problems in
pediatrics; the subjective sensation of bloating with or with-
out a visible increase of abdominal distension is one of the
most common complaints faced by pediatric gastroenterol-
ogists and general pediatricians in their clinical practice.
Gas-related symptoms are included in the functional
gastrointestinal disorders (FGID) as there is no evidence of
morphological or biochemical abnormalities. When the
symptoms are mild or episodic, reassurance and dietary
changes may be sufficient. However when children suffer of
recurring symptoms of bloating, flatulence (wind), disten-
sion and abdominal discomfort/pain with significant
impairment for children and their family, it is reasonable to
have a more proactive approach to reduce symptoms.
The proposed pathophysiology of gas-related symptoms in-
cludes a variety of different and overlapping mechanisms,
which are difficult to recognize in clinical practice [4,5].
Bloating and distension together with belching,
aerophagia and flatulence, have been attributed to exces-
sive intestinal gas accumulation, impaired handling ofTable 3 Rates of patients in whom FPS-R improved or




(N = 27) (N = 25)
Pts with difference of
FPS-R score < −0.5, n (%) 14 (52%) 8 (32%) 0.15
Pts with difference of
FPS-R score > 0.5, n (%)
3 (11%) 6 (24%) 0.22gas in the small intestine, impaired clearance from
the proximal colon, psychological factors, altered gut
microflora, incomplete digestion and malabsorption of
carbohydrates [20].
We did not investigate the dietary habits of children
before and during our study. Parents were instructed to
continue with their usual diet over the study period in
order to avoid any possible impact from a change of diet
to the study results. According to clinical history and
parents’ opinion, the symptoms were apparently related to
meals: a fact which is also demonstrated by the bloating
severity score which was lowest at the time of waking up
and steadily increased during the day.
There are different strategies that may reduce intestinal
gas including active charcoal, simethicone etc. [9,10]. Re-
cently, the use of antibiotics seems to provide significant
relief of functional GI symptoms, bloating and abdominal
pain, but the need for repeated treatment cycles may have
an important impact on the intestinal bacterial flora
[21,22], especially in children.
In recent years, an alternative approach, based on the
administration of α-galactosidase, an enzyme with
amylase-like activity, seems to be effective in reducing
the production of intestinal gas by breaking down non
digestible oligosaccharides (NDO) before they reach the
lower intestine. Indeed, the human intestine does not
contain the enzyme required to digest NDO and their
consequent incomplete digestion produces increased
bacterial fermentation generating hydrogen, methane and
carbon dioxide [13-15].
Our results show that in children with predominant
gas-related symptoms, the administration of α-galactosi-
dase significantly reduces global distress, bloating and
flatulence compared to placebo, but does not significantly
reduce other symptoms such as abdominal distension and
spasms which generally occur in functional gastrointes-
tinal disorder. However this is consistent with the mech-
anism of action of α-galactosidase. The reduced formation
Figure 2 Change of FPS-score in any patient before and after the treatment.
Figure 3 Physician overall evaluation at end of treatment and at follow-up.
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other beneficial effects on distension of colon segments
and abdomen.
The strength of our findings is mitigated by the findings
in some secondary efficacy endpoints. No significant
changes were observed between α-galactosidase and
placebo for the “physician’s overall evaluation” at end of
treatment and at follow-up. This may be related to the fact
that this global evaluation may include other symptoms
(in addition to bloating) which are poorly responsive to
α-galactosidase such as symptoms that are not gas-related.
The effect of α-galactosidase on gas related symptoms
does not appear to be long-lasting. The improvement
observed at the end of treatment was not sustained after
2 weeks of follow-up but this is consistent with the
mechanism of action of the enzyme.
The limitations of our study are the short duration of
treatment (2 weeks only) and the relatively small sample
compared to trials in adult populations.
There is not much information about placebo response
on gas related symptoms in children in literature. In our
study, we did not see apparent difference in the placebo
response between children of less and above 8 years.
There were no reported adverse effects during the study.
Based on our study there is no safety issue related to the
use of α-galactosidase in children with bloating and
gas-related symptoms. This is also supported by clinical
practice and post-marketing experience on the use of
α-galactosidase in children as well as in adults.
Oral α-galactosidase was effective in the short-term
treatment of gas-related symptoms in children who were
referred to specialist care. Its use is also supported by
non-toxicity, good tolerability and availability of the
formulation in drops, suitable for pediatric patients.
Further longer and larger randomized controlled clinical
trials are needed to assess the efficacy and usefulness of
α-galactosidase in children with gas-related symptoms
and to identify subgroups of patients who are more likely
to respond (or fail) to this agent.
A detailed medical history may help physicians to
recognize children in whom, based on the medical history,
food appears to induce or favor gas-related symptoms.
A symptomatic treatment approach for these children
could be beneficial: if there is no significant improvement
in the main target symptom or overall symptoms after
2 weeks, a different alternative approach should be
considered.
This study was placebo-controlled, as currently there is
no reference treatment for gas-related symptoms in
FGID. The evidence of efficacy of antiflatulents such as
simethicone and activated charcoal is weak, together with
that of probiotics, such as different strains of Lactobacillus
or Bifidobacterium spp. Similarly, there does not appear
to be any robust evidence for using antispasmodics,prokinetics or non-absorbable antibiotics if the target
symptom is bloating. Our study was carried out in
children who predominantly had bloating and gas-related
symptoms, with no significant abdominal pain. Conse-
quently, the beneficial results obtained in this study
cannot be considered valid for children suffering from dif-
ferent variants of functional gastrointestinal disorder (IBS-
predominant constipation or IBS-predominant diarrhea).
We acknowledge the limitations of the present study.
The number of included patients is limited and their age
range is wide. In addition, although the “gas-related
syndrome” may be considered as a functional digestive
syndrome characterized by non specific gastrointestinal
symptoms, including bloating, flatulence, abdominal
distension and discomfort that the patient attributes to an
excess of abdominal gas, however this condition is poorly
defined and overlaps with IBS. All our patients meet
Rome III criteria for IBS and the American College of
Gastroenterology IBS Task Force recommends that
further investigations are unnecessary in young patients
without alarm features with the exception of celiac disease
serology. However, different diagnoses, including lactose
intolerance, fructose intolerance, small bowel bacterial
overgrowth and aerophagia, were not formally investigated
in our patients. Finally, although we instructed the parents
of our patients to continue with their usual diet over the
study period, the dietary habits of our children were not
formally recorded in diary during the study. For this
reason, we can not relate the symptoms to the type of diet
(high and low fiber intake).
This study has shown for the first time that pediatric
patients with predominant gas-related symptoms had a
better response than placebo in the short term use of oral
α-galactosidase. The improvement of symptoms becomes
evident in a few days, in particular the reduction of the
severity and frequency of bloating and flatulence. This
effect tends to disappear in half of patients 2 weeks after
treatment withdrawal.
Conclusions
In conclusion, oral α-galactosidase was effective and very
well tolerated in the treatment of bloating and gas-related
symptoms in children and adolescents aged 4 – 17 years.
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